Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

Overcoming Challenges in the Cellular Therapy Laboratory

Looking for potential solutions to your cell therapy manufacturing challenges?

This presentation identifies the challenges associated with early-stage cell therapy manufacturing and reviews potential solutions focusing on recent advances in cellular therapy—from mesenchymal stromal cells (MSCs) to tumor-specific T cells.

More specifically, Dr. Hanley will discuss:

  • Manufacturing cells in an academic good manufacturing practice (GMP) facility
  • Meeting the demands of investigators
  • Overcoming challenges to expand these therapies

About The Presenter:

Patrick J. Hanley, PhD

Director, GMP for Immunotherapy, Children's National, and Assistant Professor, George Washington University (Washington, DC, USA)

Dr. Hanley is the director of the class 10,000 GMP facility at Children's National Health System, which is charged with manufacturing novel cellular therapies for the Program for Cell Enhancement and Technologies for Immunotherapy (CETI) under investigational new drug (IND) applications, as well as processing standard-of-care stem cell transplant products. He is also responsible for all follow-up and immune reconstitution testing performed on patients treated on CETI's protocols. Trained as an immunologist, Dr. Hanley has an extensive background and interest in cellular therapy.

To access the webinar, please provide the following information:

Fields marked * are required.


{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{$index+1}}. {{s.label}}